Recombinant Bovine Platelet-activating factor receptor (PTAFR)

What expression systems are used for producing recombinant bovine PTAFR?

The most common expression system for producing recombinant bovine PTAFR is Escherichia coli (E. coli). This bacterial expression system is preferred for its high yield, cost-effectiveness, and established protocols. The protein is typically expressed with an N-terminal His-tag to facilitate purification using affinity chromatography techniques. For functional studies requiring post-translational modifications, mammalian expression systems may be more appropriate, though this approach is less common for basic structural studies .

When designing experiments, researchers should consider the limitations of bacterial expression systems, particularly the absence of post-translational modifications that might be present in the native bovine protein. For studies focused on receptor signaling or ligand binding, additional validation with naturally expressed PTAFR is recommended.

What are the optimal storage conditions for recombinant bovine PTAFR preparations?

Recombinant bovine PTAFR should be stored at -20°C or preferably -80°C upon receipt. To maintain protein stability, aliquoting is necessary to avoid repeated freeze-thaw cycles, which can lead to protein degradation. For working stocks, short-term storage at 4°C for up to one week is acceptable. The lyophilized form of the protein offers greater stability during storage than reconstituted solutions .

For long-term storage, it is recommended to add glycerol (final concentration of 5-50%, with 50% being optimal) to the reconstituted protein solution before aliquoting. This practice helps prevent protein degradation during the freezing process. Researchers should document the date of reconstitution and number of freeze-thaw cycles for each aliquot to ensure experimental reproducibility.

What is the recommended protocol for reconstituting lyophilized recombinant bovine PTAFR?

For optimal reconstitution of lyophilized recombinant bovine PTAFR:

• Briefly centrifuge the vial before opening to ensure the powder is at the bottom of the tube

• Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL

• Add glycerol to a final concentration of 5-50% (50% is recommended) for storage stability

• Prepare small aliquots to avoid repeated freeze-thaw cycles

• Store aliquots at -20°C or -80°C for long-term use

It's important to note that the buffer composition (Tris/PBS-based buffer with 6% Trehalose, pH 8.0) should be considered when designing experiments to avoid potential buffer incompatibilities with downstream applications.

How can researchers validate the activity and specificity of recombinant bovine PTAFR?

Validating recombinant bovine PTAFR activity requires multiple complementary approaches:

• SDS-PAGE analysis: Confirm protein purity (>90% as the standard threshold) and expected molecular weight

• Western blotting: Verify specificity using anti-PTAFR and anti-His antibodies

• Binding assays: Test functional activity through ligand binding studies with platelet-activating factor (PAF)

• Cell-based assays: Evaluate receptor activation in transfected cells by measuring calcium mobilization or downstream signaling pathways

• Competitive binding assays: Use known PTAFR antagonists to confirm binding specificity

For quantification in tissue samples, researchers should employ RT-qPCR (as demonstrated in AD mouse models) with appropriate housekeeping genes for normalization. Protein levels can be assessed via immunofluorescence staining, as performed in hippocampal tissues from APP/PS1 mice .

What experimental models are most appropriate for studying PTAFR's role in neuroinflammation?

Based on current research, several experimental models have proven effective for studying PTAFR in neuroinflammation:

• APP/PS1 double transgenic mice: This AD mouse model has demonstrated significant upregulation of PTAFR expression at both mRNA and protein levels in hippocampal tissue. These mice show age-dependent development of Aβ plaques and cognitive deficits, making them suitable for longitudinal studies of PTAFR's role in disease progression .

• LPS+Aβ-induced BV2 microglial cells: This in vitro model simulates neuroinflammatory conditions relevant to AD. BV2 cells treated with lipopolysaccharide (LPS) and amyloid beta (Aβ) show significant upregulation of PTAFR, making this a useful model for mechanistic studies and drug screening .

• Primary microglial cultures: For more physiologically relevant studies, primary microglia isolated from bovine brain tissue can be stimulated with inflammatory mediators to study PTAFR expression and signaling.

When designing experiments, researchers should carefully consider the timepoint of analysis, as PTAFR expression changes with disease progression. In APP/PS1 mice, 12-month-old animals show significantly elevated expression compared to age-matched controls .

How does PTAFR function in the microglia-mediated neuroinflammatory response?

PTAFR has been identified as a critical mediator in the microglia-mediated neuroinflammatory response. Research indicates that PTAFR exaggerates microglia-mediated neuroinflammation through the IL10-STAT3 signaling pathway. The mechanism involves:

• Increased PTAFR expression in activated microglia

• Enhanced production of inflammatory cytokines and chemokines

• Altered microglial phenotype toward a pro-inflammatory state

• Exacerbation of neuronal damage through microglial-mediated neurotoxicity

This pathway has been demonstrated in both in vivo (APP/PS1 mice) and in vitro (LPS+Aβ-induced BV2 cells) models. The upregulation of PTAFR correlates with AD progression markers, including MMSE scores, Braak staging, and neurofibrillary tangle scores, suggesting its potential utility as a biomarker for disease progression .

For researchers investigating this pathway, inhibition studies using PTAFR antagonists or siRNA-mediated silencing would provide valuable insights into the causal relationship between PTAFR activation and neuroinflammatory outcomes.

What molecular docking approaches are suitable for studying PTAFR interactions with potential therapeutic compounds?

For studying PTAFR interactions with potential therapeutic compounds, the Molecular Operating Environment (MOE) software has been successfully employed. The approach should include:

• Protein structure preparation: Using crystallographic data or homology models of PTAFR

• Ligand preparation: Optimizing 3D structures of candidate compounds

• Binding site identification: Defining the binding pocket based on known interactions

• Docking simulation: Evaluating binding poses and interaction energies

• Scoring: Using S-values (where S < -7 indicates significant binding probability)

Previous docking studies have identified potential interactions between PTAFR and several compounds including EGCG (S = -7.7826), curcumin (S = -7.5698), and donepezil (S = -7.5199). Compounds with planar structures and multiple benzene rings showed higher binding probabilities compared to those with stereo conformations .

For researchers pursuing this approach, it's important to validate computational findings with experimental binding assays and functional studies to confirm the physiological relevance of the predicted interactions.

What evidence supports PTAFR as a potential biomarker for neurodegenerative diseases?

Several lines of evidence support PTAFR's potential as a biomarker for neurodegenerative diseases, particularly Alzheimer's Disease:

• Gene expression analysis: Screening of GEO database cohorts (GSE1297, GSE63063, GSE110226) identified PTAFR as significantly correlated with AD severity markers including MMSE score, Braak staging, and neurofibrillary tangle scores .

• Animal model validation: 12-month-old APP/PS1 transgenic mice showed significantly upregulated PTAFR expression in both hippocampal tissue and peripheral blood compared to age-matched controls .

• Correlation with pathology: PTAFR expression correlates with inflammatory processes that precede Aβ plaque formation, potentially allowing for earlier detection than current biomarkers .

• Accessibility in peripheral samples: Importantly, PTAFR elevation was detectable in peripheral blood, making it potentially valuable as a non-invasive biomarker, unlike CSF-based markers that require lumbar puncture .

For researchers exploring PTAFR as a biomarker, longitudinal studies correlating PTAFR levels with disease progression would be valuable to establish its predictive validity. Additionally, comparisons with established biomarkers (Aβ42, T-tau, p-tau) would help position PTAFR within the existing diagnostic framework.

What methodologies are most effective for quantifying PTAFR expression in clinical samples?

For quantifying PTAFR expression in clinical samples, several complementary methodologies have proven effective:

• RT-qPCR: For mRNA quantification in both tissue and peripheral blood samples. This method should include appropriate reference genes for normalization and follow MIQE guidelines for reproducibility .

• Western blotting: For protein-level quantification in tissue samples, providing information on protein expression levels and potential post-translational modifications .

• Immunofluorescence staining: For spatial localization of PTAFR in tissue sections, allowing assessment of cell-type specific expression patterns .

• Flow cytometry: For quantifying PTAFR expression on specific cell populations in peripheral blood samples.

• ELISA: For detecting soluble PTAFR or PTAFR fragments in plasma, serum, or cerebrospinal fluid.

When implementing these methods, researchers should establish standardized protocols that include appropriate positive and negative controls, detailed sample handling procedures, and consistent analysis parameters to ensure reproducibility across different laboratories and patient cohorts.

How is PTAFR expression in platelets associated with thrombotic risk in inflammatory conditions?

Recent research has identified a potential connection between PTAFR expression in platelets and thrombotic risk in inflammatory conditions, particularly in COVID-19. Key findings include:

• Significant hyperexpression of PTAFR and PF4 genes in unvaccinated and hospitalized COVID-19 patients compared to healthy controls .

• This hyperexpression correlates with disease severity and clinical variables including hospitalization outcomes .

• The association suggests PTAFR may contribute to the prothrombotic state observed in severe COVID-19, characterized by elevated coagulation markers and increased platelet activation and aggregation .

For researchers investigating this relationship, it would be valuable to design studies that:

• Compare PTAFR expression levels with established markers of platelet activation and aggregation

• Examine the correlation between PTAFR expression and clinical thrombotic events

• Investigate whether PTAFR antagonists could modulate platelet activation in inflammatory conditions

Methodologically, flow cytometry analysis of platelets with PTAFR-specific antibodies combined with activation markers would provide insights into the relationship between PTAFR expression and platelet reactivity.

What experimental approaches can distinguish between PTAFR-mediated effects and other inflammatory pathways in platelets?

To distinguish PTAFR-mediated effects from other inflammatory pathways in platelets, researchers should consider these experimental approaches:

• Specific PTAFR antagonists: Using compounds like CV-3988, WEB-2086, or rupatadine in parallel with pathway-specific inhibitors for non-PTAFR inflammatory mediators

• Genetic approaches: CRISPR-Cas9 editing or siRNA knockdown of PTAFR in platelet precursor cells or appropriate cell lines

• Receptor occupancy assays: Using labeled PAF to determine receptor occupancy and competition with potential antagonists

• Downstream signaling analysis: Measuring calcium mobilization, phospholipase C activation, and protein kinase C phosphorylation as PTAFR-specific readouts

• Combined inhibition studies: Systematic inhibition of multiple pathways to identify synergistic or independent effects

When designing these experiments, appropriate controls are essential, including isotype-matched antibodies for flow cytometry, vehicle controls for pharmacological agents, and scrambled siRNA sequences for genetic approaches.

How can researchers leverage cross-species comparisons of PTAFR to enhance translational research?

Cross-species comparisons of PTAFR offer valuable opportunities for translational research:

• Sequence homology analysis: Compare bovine PTAFR with human, murine, and other mammalian species to identify conserved domains crucial for function and species-specific variations that might affect drug interactions.

• Function conservation studies: Evaluate whether bovine PTAFR responses to ligands and inhibitors parallel those of human PTAFR, particularly in inflammatory cascades relevant to disease models.

• Cross-species validation platforms: Develop systems where findings in bovine models can be rapidly validated in human cell lines or samples to accelerate translational discoveries.

• Evolutionary context analysis: Examine how PTAFR function has evolved across species to gain insights into its fundamental biological roles versus species-specific adaptations.

When implementing this approach, researchers should systematically compare PTAFR expression patterns, signaling pathways, and responses to pharmacological agents across species. This would facilitate more accurate extrapolation from animal models to human disease processes.

What role might PTAFR play at the intersection of neuroinflammation and cerebrovascular pathology?

The potential role of PTAFR at the intersection of neuroinflammation and cerebrovascular pathology represents an emerging research area:

• PTAFR expression in both platelets and microglia suggests it may serve as a bridge between vascular and neural inflammatory processes .

• In neurodegenerative conditions like AD, both microglial activation and vascular dysfunction contribute to pathology, with PTAFR potentially linking these processes.

• The connection between PTAFR hyperexpression in COVID-19 patients and their thrombotic complications suggests similar mechanisms might be relevant in cerebrovascular aspects of neurodegeneration .

For researchers exploring this intersection, experimental approaches could include:

• Co-culture systems using microglia and brain endothelial cells to study PTAFR-mediated cross-talk

• Animal models that combine vascular and neurodegenerative features

• Analysis of PTAFR expression in different cell types within the neurovascular unit

This research direction could yield insights into how systemic inflammatory conditions affect neurological function through PTAFR-mediated mechanisms.